- Investing Ideas
- Australian Pharmaceuticals & Biotech High Insider Buying
Australian Pharmaceuticals & Biotech High Insider Buying
Results
25
Stocks with high levels of insider buying the past 3 months and good analyst coverage.
25 companies
CSL
Market Cap: AU$52.2b
Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
CSL
AU$107.51
7D
9.8%
1Y
-55.0%
Telix Pharmaceuticals
Market Cap: AU$4.6b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
TLX
AU$13.60
7D
2.2%
1Y
-45.1%
Mesoblast
Market Cap: AU$2.5b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$1.95
7D
-4.9%
1Y
8.6%
PYC Therapeutics
Market Cap: AU$1.2b
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
PYC
AU$1.22
7D
-1.2%
1Y
3.0%
Racura Oncology
Market Cap: AU$468.1m
Operates as a Phase 3 clinical biopharmaceutical company for cancer care.
RAC
AU$2.40
7D
-11.1%
1Y
111.5%
Orthocell
Market Cap: AU$200.1m
A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally.
OCC
AU$0.73
7D
-5.8%
1Y
-41.0%
Bioxyne
Market Cap: AU$195.3m
Manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan.
BXN
AU$0.086
7D
0%
1Y
218.5%
Actinogen Medical
Market Cap: AU$122.1m
A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.
ACW
AU$0.034
7D
-5.6%
1Y
70.0%
Arovella Therapeutics
Market Cap: AU$81.0m
A biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally.
ALA
AU$0.067
7D
-2.9%
1Y
-10.7%
Radiopharm Theranostics
Market Cap: AU$70.9m
A clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.
RAD
AU$0.02
7D
0%
1Y
-23.1%
Botanix Pharmaceuticals
Market Cap: AU$62.9m
Operates as a commercial dermatology company in Australia and the United States.
BOT
AU$0.023
7D
4.5%
1Y
-92.3%
Entropy Neurodynamics
Market Cap: AU$50.6m
A clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States.
ENP
AU$0.031
7D
-6.1%
1Y
3.3%
Nexsen
Market Cap: AU$50.0m
Operates as a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural, and biosecurity applications.
NXN
AU$0.25
7D
-2.0%
1Y
n/a
Trajan Group Holdings
Market Cap: AU$49.6m
Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.
TRJ
AU$0.33
7D
3.2%
1Y
-53.6%
Neurizon Therapeutics
Market Cap: AU$48.5m
A clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases.
NUZ
AU$0.065
7D
8.3%
1Y
-59.4%
Imugene
Market Cap: AU$37.8m
A clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.
IMU
AU$0.091
7D
-1.1%
1Y
-82.2%
BCAL Diagnostics
Market Cap: AU$25.8m
A screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer.
BDX
AU$0.07
7D
-5.4%
1Y
20.7%
Peak Processing
Market Cap: AU$17.4m
Manufactures, distributes, and sells recreational cannabis products in Canada and the United States.
PKP
AU$0.015
7D
0%
1Y
-42.3%
OncoSil Medical
Market Cap: AU$17.3m
A medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma.
OSL
AU$0.56
7D
29.9%
1Y
-37.9%
IDT Australia
Market Cap: AU$14.5m
Engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States.
IDT
AU$0.034
7D
-5.6%
1Y
-66.0%
Firebrick Pharma
Market Cap: AU$11.1m
Engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally.
FRE
AU$0.039
7D
-7.1%
1Y
-45.8%
Epsilon Healthcare
Market Cap: AU$8.9m
Engages in the healthcare business in Australia.
EPN
AU$0.023
7D
0%
1Y
n/a
Vectus Biosystems
Market Cap: AU$8.3m
Engages in the medical research and development activities in Australia.
VBS
AU$0.14
7D
8.0%
1Y
181.3%
Percheron Therapeutics
Market Cap: AU$6.1m
Engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia.
PER
AU$0.004
7D
-20.0%
1Y
-60.0%
Chimeric Therapeutics
Market Cap: AU$4.0m
A clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia.
CHM
AU$0.075
7D
-8.5%
1Y
-81.3%